[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autonomic-nervous-system-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autonomic-nervous-system-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,97,132,157],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100640580","structured-combined-exercise-program-in-postmenopausal-women-effects-on-heart-rate-variability-and-menopausal-symptoms-100640580",false,"NCT07615790","Structured Combined Exercise Program in Postmenopausal Women: Effects on Heart Rate Variability and Menopausal Symptoms","The Effect of a Structured Combined Exercise Program on Heart Rate Variability and Menopausal Symptoms in Postmenopausal Women: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Women in the postmenopausal period\n* Aged between 45 and 65 years\n* Able to communicate and cooperate with the researchers\n* Not participating in another structured exercise program\n* Willing to participate voluntarily in the study\n\nExclusion Criteria:\n\n* Presence of severe cardiovascular, neurological, orthopedic, or psychiatric disease\n* Hormone replacement therapy use during the study period\n* Cognitive impairment affecting participation\n* Uncontrolled hypertension or other unstable medical conditions\n* Regular participation in structured exercise training within the last 6 months\n* Smoking or alcohol use that may affect heart rate variability measurements","FEMALE","45 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn whether a structured combined exercise program can improve heart health, menopausal symptoms, sleep quality, and quality of life in postmenopausal women aged 45 to 65 years.\n\nThe main questions it aims to answer are:\n\nDoes the exercise program improve heart rate variability, which shows how well the heart is controlled by the nervous system? Does the exercise program lower menopausal symptoms? Does the exercise program improve sleep quality and quality of life?\n\nResearchers will compare women who join the exercise program with women who continue their usual daily activities.\n\nParticipants in the exercise group will take part in a supervised exercise program for 12 weeks. They will exercise 2 days each week. Each session will last 45 minutes and will include warm-up, balance, strengthening, coordination, flexibility, and cool-down exercises.\n\nParticipants in the control group will continue their usual daily activities during the study.",[27,28,29,30],"Postmenopausal","Menopausal Symptoms","Autonomic Nervous System Diseases","Sleep Wake Disorders",[32,33,34,35,36,37,38],"Structured combined exercise","Postmenopausal women","Heart rate variability","Cardiac autonomic function","Menopausal symptoms","Sleep quality","Quality of life","RECRUITING","2026-05-28",{"date":42,"type":43},"2026-05-29","ACTUAL",{"date":45,"type":43},"2026-04-27",{"date":47,"type":21},"2026-09",{"name":49,"class":50},"Fenerbahce University","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":51},"100638580","noninvasive-ca-monitoring-validation-and-autonomic-modulation-in-aneurysmal-subarachnoid-hemorrhage-100638580","NCT07577739","Noninvasive CA Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage","Non-Invasive Cerebral Autoregulation Monitoring Validation and Autonomic Modulation in Aneurysmal Subarachnoid Hemorrhage: A Two-Component Prospective Study of EVD Clamping Validation, CA Natural History, and the Effects of Cervical Sympathetic Block and Transcutaneous Auricular Vagal Nerve Stimulation on Cerebral Autoregulation Parameters","Inclusion Criteria (Component 1 - All Enrolled Participants):\n\n* Age 18 years or older\n* Primary diagnosis of aneurysmal subarachnoid hemorrhage (aSAH), confirmed by imaging\n* Admitted to the NSICU at Clements University Hospital, UT Southwestern Medical Center\n* Informed consent obtained from subject or legally authorized representative (as defined under Texas Health and Safety Code Section 166.039)\n* Brain4Care extensometry sensor placeable at an appropriate cranial site not occluded by surgical dressings or EVD hardware\n* Open EVD with active continuous ICP monitoring (required for EVD clamping sub-protocol only; not required for Aims 2 or 3)\n\nExclusion Criteria (Component 1):\n\n* Age younger than 18 years\n* Prisoner status\n* Primary NSICU admission diagnosis other than aSAH\n* Active declination by subject or legally authorized representative\n* Brain4Care sensor not placeable at any accessible cranial site\n* Active clinical deterioration making research monitoring impractical at time of approach\n* Physician-of-record declining research enrollment for clinical reasons\n* Inability to provide informed consent in English\n* Known pregnancy at time of enrollment\n\nAdditional Inclusion Criteria for Component 2 (Aim 3 - CSB and taVNS):\n\n* At least one successful EVD clamping session completed\n* PI documentation of Component 2 operational readiness, co-signed by qualified co-investigator or Department Director\n* INR 1.5 or less and platelet count 50,000\u002FuL or greater within 24 hours prior to each CSB procedure\n* No active infection or cellulitis at right anterolateral neck\n* No known allergy to ropivacaine or amide local anesthetics\n* No contralateral phrenic nerve palsy or severe pre-existing respiratory compromise\n* No cardiac pacemaker or implanted cardiac device contraindicating taVNS\n* No allergy to electrode adhesive materials\n* Continuous cardiac telemetry active and interpretable\n* Resting HR 60 bpm or greater on two readings within 24 hours prior to session\n* No current use of Class I or III antiarrhythmic medications\n* No clinically significant AV conduction abnormality\n\nAdditional Exclusion Criteria for Component 2:\n\n* Prior ipsilateral right-sided cervical surgery, radiation, or known anatomical distortion precluding safe C6 approach\n* Hemodynamic instability with active vasopressor escalation at time of planned CSB\n* Active uncontrolled tachyarrhythmia or bradyarrhythmia at time of taVNS session\n* Physician-of-record declining autonomic modulation procedures for any clinical reason\n* Known or suspected pregnancy","ALL","18 Years",{"count":62,"type":21},300,[24],"This is a two-component prospective study of adult aneurysmal subarachnoid hemorrhage (aSAH) patients admitted to the Neurosciences Intensive Care Unit (NSICU) at UT Southwestern Medical Center. Component 1 (active upon IRB approval) validates Brain4Care (B4C) extensometry-derived noninvasive cerebral autoregulation (CA) indices against invasive ICP-derived equivalents in aSAH patients with open external ventricular drains (EVDs), and characterizes the prospective natural history of multi-modal CA parameter evolution through the delayed cerebral ischemia (DCI) window (admission through Day 14). Component 2 (activated upon PI readiness declaration) assesses the within-subject effect of cervical sympathetic block (CSB) and transcutaneous auricular vagal nerve stimulation (taVNS) on CA parameters in enrolled aSAH patients.",[66,67,68,29],"Subarachnoid Hemorrhage, Aneurysmal","Delayed Cerebral Ischemia","Cerebral Vasospasm",[70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86],"aneurysmal subarachnoid hemorrhage","delayed cerebral ischemia","cerebral autoregulation","CPPopt","MAPopt","pressure reactivity index","Brain4Care","cervical sympathetic block","stellate ganglion block","transcutaneous auricular vagal nerve stimulation","taVNS","autonomic modulation","EVD clamping","external ventricular drain","near-infrared spectroscopy","noninvasive ICP monitoring","neurocritical care","NOT_YET_RECRUITING","2026-05-04",{"date":90,"type":43},"2026-05-11",{"date":92,"type":21},"2026-07",{"date":94,"type":21},"2030-06",{"name":96,"class":50},"University of Texas Southwestern Medical Center",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":59,"minAge":105,"maxAge":18,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":51},"100636062","effect-of-beetroot-juice-on-cardiovascular-and-autonomic-responses-to-exercise-in-adults-with-type-2-diabetes-100636062","NCT07560800","Effect of Beetroot Juice on Cardiovascular and Autonomic Responses to Exercise in Adults With Type 2 Diabetes","Effect of Beetroot Juice on Cardiovascular and Autonomic Responses During and After Exercise in Adults With Type 2 Diabetes","DiaBEET","Inclusion Criteria:\n\n* Clinically diagnosed Type 2 Diabetes Mellitus\n* Aged 40 to 65 years\n* Not treated with insulin\n* Stable diabetes medication regimen for at least 3 months\n* Able to understand the study information and provide informed consent\n* Able to safely perform light-to-moderate cycling exercise\n\nExclusion Criteria:\n\n* Current or recent use of insulin\n* Use of organic nitrates (e.g., glyceryl trinitrate) or phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil)\n* Use of systemic antibiotics within the specified preparation period or regular use of antiseptic\u002Fantibacterial mouthwash during study participation\n* Use of supplements known to interfere with nitric oxide metabolism within the defined preparation period\n* Unstable or clinically significant cardiovascular disease\n* Uncontrolled hypertension or any condition that makes exercise unsafe\n* Chronic kidney disease, history of kidney stones, or other relevant renal conditions\n* Neurological, musculoskeletal or systemic disorders that impair safe participation\n* Known or suspected allergy or intolerance to beetroot, lemon or any component of the study products\n* Pregnancy or breastfeeding\n* Inability to comply with study preparation requirements","40 Years",{"count":107,"type":21},20,[24],"This study will investigate whether a single dose of beetroot juice can improve cardiovascular responses and recovery after exercise in adults with Type 2 Diabetes.\n\nType 2 Diabetes is associated with higher blood pressure, impaired blood vessel function, and reduced autonomic control of the heart, all of which increase cardiovascular risk and may affect how the body responds to and recovers from physical activity. Beetroot juice is naturally rich in dietary nitrate, which is converted in the body into nitric oxide, a molecule that helps blood vessels relax and improve blood flow. While these effects have been demonstrated in healthy individuals, less is known about their impact in people with Type 2 Diabetes.\n\nIn this study, approximately 16 to 20 adults aged 40 to 65 years with Type 2 Diabetes will take part. After an online screening and consent process, eligible participants will attend two laboratory visits at Oxford Brookes University. In a randomised, double-blind, placebo-controlled crossover design, participants will receive beetroot juice during one visit and a nitrate-depleted placebo during the other visit.\n\nDuring each visit, participants will undergo physiological measurements, including blood pressure, heart rate, oxygen saturation, and capillary blood glucose. Participants will then complete a short session of supervised, light-to-moderate cycling exercise. Measurements will continue during the recovery period to assess how quickly the cardiovascular system returns to resting levels.\n\nThe main outcomes are systolic blood pressure and heart rate variability during recovery, which reflect cardiovascular regulation and autonomic function. Secondary outcomes include diastolic blood pressure, heart rate, blood glucose, and markers related to nitric oxide availability.\n\nThis study may help determine whether a simple, dietary-based intervention such as beetroot juice can support cardiovascular function and improve recovery after exercise in people living with Type 2 Diabetes.",[111,112,29],"Type 2 Diabetes Mellitus","Hypertension",[114,115,116,34,117,118,119,120,121,122],"Beetroot juice","Dietary nitrate","Nitric oxide","Autonomic function","Blood pressure","Exercise recovery","Submaximal exercise","Endothelial function","Crossover trial","2026-04-28",{"date":125,"type":43},"2026-05-01",{"date":127,"type":21},"2026-04-02",{"date":129,"type":21},"2026-07-31",{"name":131,"class":50},"Oxford Brookes University",{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":59,"minAge":60,"maxAge":18,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":51},"100628956","basic-and-clinical-study-of-cardiac-ganglion-catheter-ablation-for-the-treatment-of-significant-bradycardia-100628956","NCT07468383","Basic and Clinical Study of Cardiac Ganglion Catheter Ablation for the Treatment of Significant Bradycardia","Inclusion Criteria:\n\n1. Age range: 18 - 65 years old\n2. Have symptoms related to bradycardia (syncope, dizziness, blackout, palpitations, fatigue, listlessness, inability to concentrate and decreased activity endurance, etc.)\n3. Meet one of the following conditions: ①Dynamic electrocardiogram shows an average heart rate of less than 50 beats per minute or there is a heart arrest lasting more than 3 seconds during the day; ②Transient second or third degree atrioventricular conduction block without hemodynamic disorders during the day\n4. The atropine test showed that the sinus heart rate increased by ≥ 25%, or the heart rate was ≥ 90 beats per minute, or the atrioventricular conduction block was significantly improved to be no more than first-degree atrioventricular conduction block.\n\nExclusion Criteria:\n\n1. A history of severe trauma caused by bradycardia\n2. Regular use of antiarrhythmic drugs within the past 3 months\n3. Prior implantation of a cardiac pacemaker\n4. Existing implantation of, or indication for implantation of, electronic devices with pacing function, such as cardiac contractility modulators (CCMs), implantable cardioverter-defibrillators (ICDs), or cardiac resynchronization therapy (CRT) devices\n5. Bradycardia or atrioventricular block caused by medications or other reversible factors (e.g., hyperkalemia, hypothyroidism)\n6. Bradycardia or atrioventricular block associated with obstructive sleep apnea syndrome (OSAS)\n7. Coronary revascularization within the past 3 months, or unstable coronary heart disease despite standardized medical treatment or revascularization\n8. Stroke or transient ischemic attack (TIA) within the past 3 months\n9. A history of open-heart surgery\n10. Severe congenital heart disease\n11. Complicated with severe ventricular arrhythmia\n12. Severe cardiac insufficiency with left ventricular ejection fraction (LVEF) ≤ 35%\n13. Severe cardiomyopathy, such as hypertrophic obstructive cardiomyopathy (HOCM), dilated cardiomyopathy (DCM), or cardiac amyloidosis\n14. Severe aortic or mitral valve stenosis\n15. Pregnancy or lactation period\n16. Expected survival time of less than 1 year\n17. Refusal to sign the informed consent form\n18. Other conditions deemed ineligible by the researchers",{"count":139,"type":21},188,[24],"This study adopts a strategy combining basic research with clinical investigation to systematically explore the therapeutic value of cardioneuroablation in the treatment of vagally-mediated bradycardia. The study design fully considers the complexity of the scientific question and the feasibility of clinical translation. Through rigorous experimental design and standardized operational procedures, the reliability and reproducibility of the study results are ensured.",[143,29],"Symptomatic Bradycardia",[145,143,146,147],"cardioneuroablation","Efficacy","Safety","2026-03-11",{"date":150,"type":43},"2026-03-13",{"date":152,"type":43},"2025-08-01",{"date":154,"type":21},"2028-07-31",{"name":156,"class":50},"Beijing Anzhen Hospital",{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":4,"eligibilityCriteria":163,"healthyVolunteers":164,"sex":59,"minAge":165,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":51},"100534293","hutt-to-assess-cardiac-autonomic-nervous-function-100534293","NCT06236945","HUTT to Assess Cardiac Autonomic Nervous Function","Composite Autonomic Scoring Scale and HUTT to Assess Cardiac Autonomic Nervous Function: A Preliminary Study","Inclusion Criteria:\n\n* Vertical tilt test and 24-hour holter electrocardiogram were performed at the same time\n\n  * Receive treatment in our hospital.\n\nExclusion Criteria:\n\n* Taking benzodiazepines or hypotensive drugs within 24 hours\n\n  * Combined with mental illness, severe dementia, serious organ disease\n\n    * Severe arrhythmia, deep breathing and poor coordination of Valsaval movements affected the interpretation of results.",true,"12 Years","85 Years",{"count":168,"type":21},1122,"OBSERVATIONAL","Autonomic nervous system diseases can cause abnormalities in the circulatory system, leading to malignant arrhythmia and sudden cardiac death. Standardized, operable, and simplified diagnostic indicators are urgently needed to evaluate autonomic nervous function, particularly cardiac autonomic nervous function. The investigators use HUTT in order to provide data support for cardiac autonomic nervous system evaluation.",[29],"2024-09-24",{"date":174,"type":43},"2024-09-26",{"date":176,"type":43},"2024-01-31",{"date":178,"type":21},"2025-12-31",{"name":180,"class":50},"The First Hospital of Hebei Medical University"]